CETP Gets Another Go: NewAmsterdam Phase III Trial Shows Safety And Efficacy

 
• By Jessica Merrill

The first Phase III trial testing the oral CETP inhibitor obicetrapib for the treatment of high cholesterol read out positively, years after some other drugs in the class failed.  

Obicetrapib showed a benefit on LDL-C reduction in patients with HeFH • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas